We have just announced our financial calendar for 2026 with fixed dates for our financial reports and business updates plus the Annual General Meeting. The calendar can also be found on our website: https://t.co/vVYkMLay11 #EVAX

We presented new data on personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting taking place in National Harbor, Maryland. Explore the conference poster here: https://t.co/Y1J7BGTzW8, or read more in our press release:

We have just published our financial results and business update for the third quarter of 2025. We will host a conference call and webcast at 8.30 ET/14.30 CET today, join here: https://t.co/vtmQ7eBMHH Read more in our press release: https://t.co/pccuicF40J #EVAX

We expand our R&D pipeline with new AI-designed precision cancer vaccine candidate; EVX-04. EVX-04 is targeting multiple non-conventional ERV (endogenous retrovirus) tumor antigens, developed with our AI-Immunology™ platform. It is a novel therapeutic cancer vaccine candidate

We have extended our cash runway to the second half of 2027. In recent week, Evaxion has raised $7.2 million with $4.5 million coming from sale of shares in an at-the-market (ATM) offering and $2.7 million coming from exercise of investor warrants. This means we now have cash on

Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer. Dr Tayton-Martin brings broad experience of biotech company building, fund-raising, M&A, business development and operations with a strong track record of strategic partnership deals.

We invite you to attend our upcoming online webinar this Wednesday at 16:30 CEST / 10:30 AM EDT, where Professor Adnan Khattak will present and discuss the newly released two-year phase 2 clinical data from EVX-01, Evaxion’s AI-designed personalized cancer vaccine. Secure your

We are excited to report a 75% Objective Response Rate in phase 2 trial with our AI-designed personalized cancer vaccine EVX-01. Read more in our press release: https://t.co/yJg9sSyZGN #EVAX

We are delighted to announce monumental news for Evaxion: MSD has exercised their option to license vaccine candidate EVX-B3 for a cash payment of $7.5 million. Join our teleconference later today and read our press release to learn more: https://t.co/0qvJtCAyqz #EVAX

We are looking forward to a busy conference schedule in the coming months as we will be presenting data and company updates at numerous scientific and investor conferences throughout the second half of 2025. https://t.co/sYPmdbZs0b #EVAX

We just published our financial results and business update for the second quarter of 2025. We continue to execute our strategy and plans with a number of significant achievements across the company in recent months. We remain on track to achieve the milestones set for 2025.

Evaxion will provide a business update and report its second quarter 2025 financial results on Thursday, August 14, 2025, before opening of the Nasdaq CM. Our Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update

We expand our R&D pipeline with a new preventive vaccine program – EVX-B4 - targeting Group A Streptococcus (GAS), often also known as “flesh eating bacteria”. Read more: https://t.co/7rRUUmUfL3 #EVAX

We are delighted to announce a grant from the Gates Foundation funding the design of a potential new polio vaccine. Read more in our press release: https://t.co/8lTzGbfIZm #EVAX

We just published our financial results and business update for the first quarter of 2025. We have made good progress with continued execution of our strategy and plans, achieving the first two milestones for the year and are tracking towards future milestones and value